New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
07:44 EDTONTX, BAXRigosertib failure removes positive catalyst for Baxter, says Leerink
Leerink says Onconova's (ONTX) announcement last night that pivotal results of IV rigosertib in myelodysplastic syndrome failed to meet its primary endpoint as removing a positive catalyst for Baxter (BAX) since Baxter has the European rights to rigosertib. Leerink points out that Baxter had previously noted that rigosertib could ultimately be a $1B drug. However, the firm believes rigosertib was largely not reflected in estimates for Baxter and it reiterates an Outperform rating on the stock.
News For BAX;ONTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
16:25 EDTONTXOnconova reports Q4 EPS (62c), consensus (63c)
Subscribe for More Information
March 25, 2015
07:12 EDTBAXAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
March 16, 2015
09:15 EDTBAXCTI BioPharma shares should be bought on weakness, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use